gila monster glp-1 Weight Loss and monsters. Who knew? The system that turned Gila

Impact on AMD A 2025 retrospective published in JAMA Ophthalmology looked at the incidence of developing wet age-related macular degeneration (AMD) three years after initiation of treatment with GLP-1 drugs

1.9 kg with liraglutide HbA1c reduction also greater with semaglutide This direct comparison confirms semaglutides superiority, though it used diabetes doses rather than weight loss doses

Truveta and collaborators partnered on a new large-scale study that considers the potential benefits of GLP-1 RA for AUD, among those with diabetes and/or obesity

For maximum results: Yes For budget-conscious: Semaglutide still excellent For significant obesity: Tirzepatide preferred For moderate weight loss: Either works well Ongoing Research: SURMOUNT-MMO Trial: Studying tirzepatide in patients with obesity and multiple comorbidities Evaluating cardiovascular outcomes Results pending (expected 2025-2026) Future Developments: Oral tirzepatide formulations in research Monthly injection versions being studied Combinations with other therapies Understanding affordable Mounjaro alternatives helps you access tirzepatide at prices that fit your budget

A 2025 meta-analysis suggested a slightly increased pancreatitis risk overall, but no strong evidence for increased pancreatic cancer, with some nuance around background medications

PlexusDx offers the Precision Peptide Genetic Testa peptide-pathway genetic analysis that maps 14 molecular pathways, 49 peptides, and 150+ genetic insights to predict individual GLP-1 responsiveness